Abstrait

Secukinumab for recalcitrant Psoriatic Arthritis cases

Pelechas E, Voulgari PV, Drosos AA

In the pre-TNF inhibitors (TNFi) era, several recalcitrant, moderate-to-severe, psoriatic arthritis (PsA) cases have been reported [1, 2]. The available treatment options were glucocorticoids (GCs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), retinoids, and photochemotherapy, but the results were modest [3]. TNFi revolutionised the treatment for PSA, with a constant decline of the recalcitrant cases [4, 5]. TNFi are biologic disease-modifying antirheumatic drugs (bDMARDs) bearing a significant capacity to achieve low disease activity or remission having an appealing efficacy/safety profile [6, 7]. The first TNFi for moderate-to-severe PsA was etanercept [8]. Nowadays, several bDMARDs(adalimumab, infliximab, golimumab, certolizumabpegol, ustekinumab, secukinumab, ixekizumab) and targeted synthetic DMARDs are already available such astofacitinibandapremilast.